Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease

•Omadacycline showed excellent efficacy in HFS-Mab at exposures that could be achieved in >99% of patients on 300 mg/day.•Sustained sputum culture conversion (SSCC) in 8/10 patients on omadacycline 300 mg/day-based combinations vs. 1/9 on guideline-based regimens.•No toxicity was observed in any of the cases vs. 9/9 patients treated with guideline-based regimens.•Omadacycline 300 mg/day salvage therapy achieved SSCC and symptom-resolution in 3 months in one patient.